Tasly Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 6/6
Tasly Pharmaceutical Group has a total shareholder equity of CN¥13.0B and total debt of CN¥2.6B, which brings its debt-to-equity ratio to 20.2%. Its total assets and total liabilities are CN¥17.5B and CN¥4.5B respectively. Tasly Pharmaceutical Group's EBIT is CN¥1.4B making its interest coverage ratio -66.2. It has cash and short-term investments of CN¥4.9B.
Key information
20.2%
Debt to equity ratio
CN¥2.62b
Debt
| Interest coverage ratio | -66.2x |
| Cash | CN¥4.86b |
| Equity | CN¥12.98b |
| Total liabilities | CN¥4.54b |
| Total assets | CN¥17.52b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 600535's short term assets (CN¥9.6B) exceed its short term liabilities (CN¥2.9B).
Long Term Liabilities: 600535's short term assets (CN¥9.6B) exceed its long term liabilities (CN¥1.7B).
Debt to Equity History and Analysis
Debt Level: 600535 has more cash than its total debt.
Reducing Debt: 600535's debt to equity ratio has reduced from 73.6% to 20.2% over the past 5 years.
Debt Coverage: 600535's debt is well covered by operating cash flow (79.7%).
Interest Coverage: 600535 earns more interest than it pays, so coverage of interest payments is not a concern.